Zanubrutinib
- Generic Name
- Zanubrutinib
- Brand Names
- Brukinsa
- Drug Type
- Small Molecule
- Chemical Formula
- C27H29N5O3
- CAS Number
- 1691249-45-2
- Unique Ingredient Identifier
- AG9MHG098Z
- Background
Zanubrutinib is a novel Bruton's tyrosine kinase (BTK) inhibitor used for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Mantle cell lymphoma is an aggressive mature B-cell non-Hodgkin lymphoma associated with early relapse, poor clinical outcomes, and long-term survival. BTK is an enzyme that pl...
- Indication
Zanubrutinib is indicated for the treatment of:
- Associated Conditions
- Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma (MCL), Refractory Marginal Zone Lymphoma, Relapsed Marginal Zone Lymphoma, Small Lymphocytic Lymphoma, Waldenström's Macroglobulinemia (WM)
- Associated Therapies
- -
Zanubrutinib and Eltrombopag as Second-line Treatment in Adults With Primary Immune Thrombocytopenia
- Conditions
- Interventions
- First Posted Date
- 2022-05-11
- Last Posted Date
- 2022-05-11
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 150
- Registration Number
- NCT05369377
- Locations
- 🇨🇳
Peking University Insititute of Hematology, Peking University People's Hospital, Beijing, Beijing, China
The Combination of Zanubrutinib and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia
- Conditions
- Interventions
- First Posted Date
- 2022-05-11
- Last Posted Date
- 2022-05-11
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 150
- Registration Number
- NCT05369364
An Open Label Study of the Effects and Safety of Zanubrutinib in NMOSDs Adult Patients
- First Posted Date
- 2022-05-02
- Last Posted Date
- 2022-05-20
- Lead Sponsor
- Xuanwu Hospital, Beijing
- Target Recruit Count
- 20
- Registration Number
- NCT05356858
- Locations
- 🇨🇳
XuanWu Hospital, Beijing, Beijing, China
Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma
- First Posted Date
- 2022-04-13
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- iOMEDICO AG
- Target Recruit Count
- 605
- Registration Number
- NCT05326308
- Locations
- 🇩🇪
Lübecker Onkologische Schwerpunktpraxis, Lübeck, Schleswig-Holstein, Germany
🇦🇹Universitätsklinikum Salzburg, Klinik für Innere Medizin III, Salzburg, Austria
Zanubrutinib for HLH
- First Posted Date
- 2022-04-11
- Last Posted Date
- 2024-04-11
- Lead Sponsor
- Beijing Friendship Hospital
- Target Recruit Count
- 16
- Registration Number
- NCT05320575
- Locations
- 🇨🇳
Beijing Friendship Hospital, Capital Medical University, Beijing, China
ZR-CHOP in DLBCL With Specific Gene Abnormality
- First Posted Date
- 2022-03-22
- Last Posted Date
- 2022-03-22
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 62
- Registration Number
- NCT05290337
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Study of Zanubrutinib in Patients With ITP
- Conditions
- Interventions
- First Posted Date
- 2022-03-15
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT05279872
- Locations
- 🇨🇳
Peking University Insititute of Hematology, Peking University People's Hospital, Beijing, Beijing, China
A Prospective, One-arm and Open Clinical Study of Zanubrutinib in the Treatment of Immune Thrombocytopenia
- First Posted Date
- 2022-01-28
- Last Posted Date
- 2022-01-28
- Lead Sponsor
- Zhang Lei
- Target Recruit Count
- 30
- Registration Number
- NCT05214391
- Locations
- 🇨🇳
Chinese Academy of Medical Science and Blood Disease Hospital, Tianjin, Tianjin, China
Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma
- Conditions
- Diffuse Large B-Cell Lymphoma Associated With Chronic InflammationRecurrent Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedPrimary Cutaneous Diffuse Large B-Cell Lymphoma, Leg TypeLarge B-Cell Lymphoma With IRF4 RearrangementRecurrent Aggressive B-Cell Non-Hodgkin LymphomaRecurrent Intravascular Large B-Cell LymphomaRecurrent T-Cell/Histiocyte-Rich Large B-Cell LymphomaRefractory T-Cell/Histiocyte-Rich Large B-Cell LymphomaRefractory Transformed B-Cell Non-Hodgkin LymphomaHigh Grade B-Cell Lymphoma, Not Otherwise Specified
- Interventions
- First Posted Date
- 2022-01-24
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 24
- Registration Number
- NCT05202782
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸Medical College of Wisconsin, Milwaukee, Wisconsin, United States
A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell Lymphoma
- First Posted Date
- 2022-01-20
- Last Posted Date
- 2022-03-11
- Target Recruit Count
- 36
- Registration Number
- NCT05200312
- Locations
- 🇨🇳
First affiliation hospital of nanjing medical university, Nanjing, Jiangsu, China
🇨🇳Department of Haematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjin, Jiangsu, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.